Imidazoline-guanidinium receptive site in renal proximal tubule: asymmetric distribution, regulation by cations and interaction with an endogenous clonidine displacing substance
- PMID: 2153803
Imidazoline-guanidinium receptive site in renal proximal tubule: asymmetric distribution, regulation by cations and interaction with an endogenous clonidine displacing substance
Abstract
In the present report we have used [3H]idazoxan to characterize the rabbit renal imidazoline preferring site by defining its plasmalemma distribution, its regulation by cations and the type of interaction with the clonidine displacing substance (CDS), a putative endogenous ligand for the imidazoline receptor. The density of [3H]idazoxan binding sites was 12-fold higher in purified basolateral membranes than in brush-border membranes (maximal binding activity, 566 +/- 118 vs. 46 +/- 2 fmol/mg of protein). In basolateral membranes, [3H]idazoxan binding was inhibited not only by imidazoline compounds but also by guanidinium analogs such as guanabenz, amiloride, 5-(M-ethyl-N-isopropyl)amiloride and phenamylamiloride. Amiloride had no effect on the dissociation rate of [3H]idazoxan, suggesting a direct interaction of this molecule with the ligand binding site. [3H]Idazoxan binding was 80% inhibited by 150 mM K+ or Rb+. The effect of K+ appeared to occur through the interaction with an allosteric site in as much as both the apparent dissociation constant and the dissociation rate of [3H]idazoxan were increased in the presence of 75 mM K+. CDS inhibited [3H]idazoxan binding with a half-maximal effective concentration of 2 U/250 microliters. The competitive nature of CDS effect was indicated by the increase in the apparent dissociation constant of [3H]idazoxan (Kd from 3 +/- 0.3 to 8.5 +/- 0.2 nM, P less than .01) in the presence of CDS. In conclusion, our findings showed that the imidazoline-guanidinium receptive site is located mainly in the basolateral side of the tubular cell, recognizes CDS and is regulated by K+.(ABSTRACT TRUNCATED AT 250 WORDS)
Similar articles
-
Imidazoline-guanidinium and alpha 2-adrenergic binding sites in basolateral membranes from human kidney.Eur J Pharmacol. 1991 Jan 25;206(1):23-31. doi: 10.1016/0922-4106(91)90142-5. Eur J Pharmacol. 1991. PMID: 1648494
-
[Selectivity of alpha 2-adrenergic agonists for the imidazoline-guanidine and alpha 2-adrenergic receptors].Arch Mal Coeur Vaiss. 1989 Jul;82(7):1135-7. Arch Mal Coeur Vaiss. 1989. PMID: 2573323 French.
-
Nonadrenergic imidazoline binding sites on human platelets.J Pharmacol Exp Ther. 1993 Dec;267(3):1493-502. J Pharmacol Exp Ther. 1993. PMID: 8263811
-
[Imidazoline-guanidine site: a subtype of imidazoline receptors].Therapie. 1992 Nov;47(6):519-24. Therapie. 1992. PMID: 1338740 Review. French.
-
The role of imidazoline receptors in blood pressure regulation.Pharmacol Ther. 1992;54(3):231-48. doi: 10.1016/0163-7258(92)90001-g. Pharmacol Ther. 1992. PMID: 1361236 Review.
Cited by
-
LNP 906, the first high-affinity photoaffinity ligand selective for I1 imidazoline receptors.Br J Pharmacol. 2004 Jun;142(3):609-17. doi: 10.1038/sj.bjp.0705784. Br J Pharmacol. 2004. PMID: 15178642 Free PMC article.
-
Renal effects of infusion of rilmenidine and guanabenz in conscious dogs: contribution of peripheral and central nervous system alpha 2-adrenoceptors.Br J Pharmacol. 1995 Sep;116(1):1557-70. doi: 10.1111/j.1476-5381.1995.tb16373.x. Br J Pharmacol. 1995. PMID: 8564219 Free PMC article.
-
Binding of [3H]clonidine to I1-imidazoline sites in bovine adrenal medullary membranes.Naunyn Schmiedebergs Arch Pharmacol. 1993 Jul;348(1):70-6. doi: 10.1007/BF00168539. Naunyn Schmiedebergs Arch Pharmacol. 1993. PMID: 8377842
-
Agmatine, a bioactive metabolite of arginine. Production, degradation, and functional effects in the kidney of the rat.J Clin Invest. 1996 Jan 15;97(2):413-20. doi: 10.1172/JCI118430. J Clin Invest. 1996. PMID: 8567962 Free PMC article.
-
[3H]idazoxan binding to bovine adrenal medullary membranes: identification and pharmacological characterization of I2-imidazoline sites.Naunyn Schmiedebergs Arch Pharmacol. 1994 Sep;350(3):252-7. doi: 10.1007/BF00175030. Naunyn Schmiedebergs Arch Pharmacol. 1994. PMID: 7824041